Next-generation sequencing was performed by Caris® Life Sciences on the tumor from the thyroid, which showed a pathogenic p.M394fs mutation (VAF 82%) in the FLCN gene, indicative of biallelic inactivation (double hit) and supportive of a neoplastic process. The gene discussed is FLCN; the disease is neoplasm.